QL
MLTX icon

Quarry LP’s MoonLake Immunotherapeutics MLTX Stock Holding History

Quarry LP’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34K Sell
120
-21,130
-99% -$383K ﹤0.01% 1543
2026
Q1 		$396K Buy
+21,250
New +$352K 0.07% 193
2025
Q4 		– Sell
-9,001
Closed -$64.5K – 2433
2025
Q3 		$64.5K Buy
9,001
+7,201
+400% +$375K 0.01% 710
2025
Q2 		$85K Sell
1,800
-600
-25% -$24.4K 0.02% 624
2025
Q1 		$93.8K Buy
+2,400
New +$103K 0.02% 544
2024
Q3 		– Sell
-3,000
Closed -$132K – 1901
2024
Q2 		$132K Buy
3,000
+1,900
+173% +$80.5K 0.04% 261
2024
Q1 		$55.3K Buy
1,100
+250
+29% +$13.6K 0.01% 418
2023
Q4 		$51.3K Buy
+850
New +$43.8K 0.01% 324

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quarry LP's MLTX Position: Q2 2026 in Review

Quarry LP reduced its MoonLake Immunotherapeutics (MLTX) stake by 99% in Q2 2026, selling an estimated $383K and leaving 120 shares worth $2.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Quarry LP first reported a position in MLTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $396K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Quarry LP held 120 shares of MoonLake Immunotherapeutics worth $2.34K as of Q2 2026.
  • Quarry LP sold 21,130 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $383K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #1543 holding.
  • Quarry LP first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 8 quarters since.
  • Quarry LP's MoonLake Immunotherapeutics position peaked at $396K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.